Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

A Novel Pathway for a Mucosal TB Vaccine

Published: Friday, February 01, 2013
Last Updated: Friday, February 01, 2013
Bookmark and Share
Custom-designed adjuvants, developed at UB, boost immune responses against tuberculosis.

A new pathway for improving vaccines against tuberculosis has been discovered by microbiologists at the University at Buffalo in collaboration with researchers at other universities, according to a paper in the journal Mucosal Immunology, published by the Nature group.

Lead author on the study is Shabaana A. Khader, PhD, of the Department of Pediatrics, University of Pittsburgh; co-authors are Terry D. Connell, PhD, professor of microbiology and immunology in UB’s School of Medicine and Biomedical Sciences, and researchers from the University of Rochester and the University of Alabama.

The new pathway was identified in animal studies using LT-IIb, a novel, mucosal adjuvant, developed by Connell, who has shown that LT-IIb dramatically boosts the potency of vaccines that are administered to mucous membranes. Adjuvants enhance the body’s immune response against an antigen.

“This research demonstrates that the most effective vaccination against TB should target the IL-17 pathway,” says Connell, former director of UB’s Witebsky Center for Microbial Pathogenesis and Immunology.

“This observation is in stark contrast to the importance of the IFN-γ and T helper 1 pathways in combating TB infection in the body, which have been the traditional targets for TB vaccines,” he says.

“While those pathways are essential in overcoming infection, this published study indicates that they are likely to be less important in vaccination to elicit immune protection against TB,” he explains. The mechanisms that modulate IL-17-based protection are now being studied in laboratories around the world, he adds.

Connell’s lab is leading the study of LT-IIb and similar adjuvants that are derived from a unique group of bacterial proteins that belong to the type II family of bacterial heat-labile enterotoxins (HLT). These HLT are similar in structure and toxicity to cholera toxin but, interestingly, Connell notes, do not exhibit any detectible toxicities when employed as mucosal or systemic adjuvants.

“The adjuvants, which UB patented in 2008 have some unique characteristics,” says Connell.  “Depending on the type of adjuvant, one can either enhance the body’s ability to make antibodies or enhance the body’s cytotoxic response.  The great benefit of our type II HLT adjuvants is that these molecules can activate both pathways,” he says. “We can direct the type of immune response to the vaccine that is desired, whether an antibody response or a cellular response, simply by choosing one or the other type II adjuvant.”

Connell notes that there is a big push for development of mucosal vaccines against a number of pathogens in addition to TB that could be administered by some other route than injection. That’s because in the developing world, where the need for TB vaccination is greatest, it’s very difficult to store vaccines for long periods of time in conditions required for their stability, termed “the cold chain,” which is routinely required to maintain the efficacy and safety of most, if not all, injectable vaccines.

“Clearly, for use in developing areas of the world, the most optimal vaccine and adjuvant mixture would not require the ‘cold chain,’” says Connell. “Our mixtures of adjuvants and vaccines can be dried into a powder and stored on a shelf without refrigeration until needed.”

At that point, the adjuvant/vaccine powder would be added to water sterilized by boiling; the solution could then be sprayed into the nose from an atomizer.

The emergence of drug-resistant strains of Mycobacterium tuberculosis, and the more than 1.7 million deaths each year attributable to the disease, has provided a strong impetus for researchers to develop new methods to improve mucosal vaccines against tuberculosis.

Connell says the next step for this collaborative research is to identify the cellular and molecular mechanisms that underlie the capacity of LT-IIb to induce IL-17-associated immune response to antigens and pathogens.

“Once those mechanisms, have been identified, new mutant HLT can be engineered to further optimize the capacity of these adjuvants to enhance desired immune responses to candidate TB vaccines,” he says.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
Protein Teams Activate T-Cells
Caltech researchers have discovered T-cell genetic switching is controlled by four proteins acting in a multi-tiered fashion.
'Antigen-Presenting Cell' Defends Against Cancer
Through advanced imaging, researchers have identified cells that encourages increases in immune system cancer defences.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!